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The concept of mild cognitive impairment (MCI) in the general population has 
received increased attention over recent years, and is associated with risk of 
progression to Alzheimer's disease. Within Parkinson's disease (PD), MCI (PD-MCI) is 
recognized to be relatively common, with certain subtypes predicting progression to 
Parkinson's disease dementia (PDD). Considering the importance of this emerging 
entity, new diagnostic criteria have recently been proposed. Early recognition and 
accurate classification of PD-MCI could offer opportunities for novel therapeutic 
interventions.  
The object of this study was to evaluate the efficacy of MoCA, Rey and Trails A for 
the detection of MCI in PD patients and whether additional diagnostic value is 
achieved by combining the measures. 
A convenience sample of patients (n=334 after exclusions) were examined at the 
New Zealand Brain Research Institute (NZBRI). Subjects were administered the 
MoCA, TMT-Part A, RCFT Copy and RCFT Recall and classified in three categories: (a) 
Confirmed MCI (n=17), (b) Final Probable MCI (n=226) and (c) Final Possible MCI 
(n=91), based on their performance on the standardized neuropsychological tests. 
Primary outcomes using receiver operating characteristic (ROC) curve analyses 
showed that the combination of the MoCA, RCFT Copy and RCFT Recall produced 
good discrimination of the Confirmed MCI (n=17) vs. Possible MCI (n=91) (area under 
the curve [AUC]: 86.1% ) , even better for the Confirmed MCI (n=17) vs. non-MCI 
(n=337) (AUC: 93.9% ) and excellent discrimination of the Confirmed MCI (n=17) vs. 
Probable HC (n=226) (AUC: 97.2% ). The TMT Part A produced non-significant results 
in all 3 analyses. Moreover, the results demonstrated that combining the MoCA with 
the RCFT Copy and RCFT Recall provided better discrimination of MCI than the using 
single measures. Thus, researchers and clinicians should consider adding the RCFT as 
an adjunct test to the more routinely used MoCA when screening for cognitive 
impairment, given that its copy and the immediate recall trial can be completed in 





 AUC area under the curve; CI confidence interval; MMSE MiniMental State Examination; MoCA Montreal 
Cognitive Assessment; MCI; Mild Cognitive Impairment; NPV negative predictive value; PPV positive predictive 
value; PD Parkinson disease; PD-D Parkinson disease with dementia; PD-MCI Parkinson disease with mild 
cognitive impairment; Rey RCFT Rey Complex Figure Test; ROC receiver operating characteristic; Trails A TMT 
Trail Making Tests Part A . 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly




Parkinson’s disease (PD) is a neurodegenerative disease affecting over 4 million 
people over age 50 years and it is expected to double over the next 2 decades. [1] 
Diagnosing Parkinson's disease can be difficult, especially in its early stages. Even as 
the disease progresses, symptoms may be difficult to assess and may mirror other 
disorders.  
Cognitive impairment is common in Parkinson’s disease, even in the earliest disease 
stages and can range from mild impairment (PD-MCI) to florid dementia. 30% to 40% 
of PD patients eventually suffer from dementia. (Aarsland, et al., 2001) 
Neuropsychology testing has shown evidence of cognitive impairment in over 20% of 
patients who are diagnosed with Parkinson’s disease [2][3]and over 80% of PD 
patients will develop dementia over an 8 year period. [4] Dementia doubles the 
mortality risk of PD and increases nursing home placement. [5][6]. Abnormalities 
that are shown in neuropsychological tests in non-demented PD patients may 
predict the development of dementia, although the types of abnormalities are 
plenty. [7] [8][9][10] 
Within years, the concept of mild cognitive impairment (MCI) has changed from 
global cognitive measure to a cognitive syndrome with both clinical and research 
diagnostic criteria. [11][12]-[14] Mild cognitive impairment was first introduced in 
Alzheimer’s disease (AD)[11] but has been extended to other neurodegenerative 
disorders, like PD.[15] 
In general, mild cognitive impairment (MCI) refers to cognitive decline that is not 
normal for age, like basic activities of daily living, thus not severe enough to conclude 
dementia. [11] MCI does not necessarily progresses to a dementia, but its construct 
implies that may lead from normal cognition to dementia, with MCI representing a 
transitional or prodromal state. [12] 
Despite the high frequency of cognitive impairment in PD, there is no accurate 
screening tool to identify cognitive impairment in these patients.[16] Identification 
of the early stages of MCI in PD patients is important, because it predicts future 
cognitive decline, including development of PD dementia (PDD), [17]-[20] and 
worsening of health-related quality of life.[21] 
Tests such as the Mini-Mental State Examination (MMSE) [22] are insensitive to the 
cognitive impairments in PD. [23] 
 The Montreal Cognitive Assessment (MoCA) [24] was developed as a short screening 
tool for mild cognitive impairment (MCI). It is similar to the MMSE, but is more 
sensitive in identifying MCI in general population. The MoCA includes tests of the 
cognitive domains of executive and visuospatial function, memory, language and 
attention, which are affected in early PD. [3][8] A lot of studies have tried to use the 
concept of MCI in PD to define this population and a lot more will be conducted in 
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order to fulfill the necessity of detecting cognitive impairment in PD that does not 
meet criteria for dementia. [18][20] 
One longitudinal study between patients who became demented during follow-up 
and people who remained non-demented, showed that the most significant 
predictors to indicate that individuals will develop dementia are the tests of speeded 
processing of visuospatial information. [25]. Therefore, tests like the Rey Complex 
Figure Test (RCFT) and the Trail Making Test Part A (TMT Part A) were also included 
in the study with the MoCA test. The RCFT is a neuropsychological assessment that 
measures both visuospatial abilities and memory and Part A of the TMT a 




This study was conducted at Christchurch, New Zealand. Six hundred and nine (609) 
people ≤65 were recruited through newspaper advertisement, public seminars made 
to community groups in the Canterbury region and the New Zealand Brain Research 
Institute (NZBRI) database. Of the 609 volunteers only 387 remained in the study. 
Exclusion criteria included: (1) aged 85 years or older; (2) previous or current medical 
complications (i.e., multiple sclerosis, Parkinson’s disease, major coronary disease, 
stroke, cancer); (3) developmental disorders (i.e., learning disability, Autistic 
spectrum disorder); (4) major psychiatric conditions (i.e., schizophrenia, bipolar); or 
(5) current medications (i.e., antidepressants, benzodiazepines) that are likely to 
affect cognitive functioning.  
After the final classification, 17 participants were classified as Confirmed MCI, 226 as 
Final Probable MCI and 91 as Final Possible MCI. 
Standard protocol approvals, registrations, and patient consents.  
The study was approved by the Upper South Ethics Committee of the New Zealand 
Ministry of Health and informed consent was provided by all participants with 
additional consent from a significant other when required 
Neuropsychological evaluation 
A neuropsychological battery was completed by all 334 participants. . 
Neuropsychological tests were conducted on 2 sessions with a fixed order that 
balanced verbal and nonverbal materials with breaks to avoid fatigue, using three 
postgraduate psychology students including the author, trained in administering the 
neuropsychological tests.  
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The R program version 3.2.2 was used for group comparisons and ROC curve 
analyses. 
The primary ROC curve analyses tested the diagnostic performance of each 
individual screening measure, namely the MoCA, RCFT Copy, RCFT Recall, and TMT 
Part A, across pairs of groups. For the analyses relevant to MCI diagnosis in the 
general elderly population the Possible MCI and the Probable HC were treated as a 
single non-MCI group (n=317) and compared with the Confirmed MCI group (n=17). 
To specify performance detecting MCI from normal cognition, the Confirmed MCI 
group (n=17) was compared with the Probable HC group (n=226). In order to 
diagnose MCI from individuals with some cognitive impairments but not sufficient 
for a diagnosis of MCI, the Confirmed MCI group (n=17) was compared with the 
Possible MCI group (n=91). 
Binary logistic regression was performed for each of the three groups listed above. 
The analysis was conducted to examine whether diagnostic utility was achieved by 
combining the measures. In addition with the four screening measures, demographic 
data like sex, age and educational-adjusted scores were also used.  
Cross validation techniques were used to evaluate the model. The results of 10-fold 
cross validation and leave-one-out analysis cross-validation techniques were 
compared in order to determine which technique best evaluates the predictive 
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1. Confirmed MCI vs. non-MCI (Possible MCI and Probable HC combined) (n=17 
vs n=337) 
When discriminating patients with MCI from patients without MCI, the diagnostic 
utility of the different screening tests, namely MoCA, RCFT Copy and RCFT Recall, 
produced high AUCs, but in this instance the RCFT Recall appeared to perform better 
than all 3 other measures (Table 1). The optimal cut-off point, sensitivity, specificity, 
PPV and NPV for each screening instrument are listed in Table 1. The AUC for the 
RCFT Recall was significantly higher than that shown by the MoCA (AUC difference = 
8.2%, p <0.05), however the RCFT Copy (AUC difference = 10.8%, p = 0.055 (>0.05)) 
was marginally significant. The AUC for TMT Part A was significantly inferior 
compared to the MoCA, RCFT Copy and RCFT Recall A (AUC difference of 26.1% for 
the MoCA, p < 0.001; AUC difference of 23.5% for the RCFT copy, p < 0.01; and AUC 
difference of 34.3% for the RCFT recall, p < 0.001). The AUC difference between the 
MoCA and RCFT Copy was not statistically significant (AUC difference = 2.6%, p = 
0.58(>0.05)). 
Combination of the MoCA, RCFT Copy and RCFT Recall approached perfect 
separation between patients with and without MCI and were significantly superior in 
this regard compared to the AUC for the MoCA (AUC difference = 11.0%; p < 0.001) 
and the RCFT Copy (AUC difference = 13.6%; p < 0.001). The AUCs for the combined 
model and the RCFT Recall were similar. However, the difference failed to reach 
significance (AUC difference = 2.8%; p = 0.22(>0.05)), although sensitivity and PPV 
were increased by the combination model compared to the RCFT Recall. The TMT 
Part A was not statistically significant (p =0.55>0.05). The AUCs of each test are 
illustrated in Figure 1-1 and of the combination model in Figure 1-2. 
 
Table 1-1. Diagnostic Performance of MoCA, RCFT Recall, RCFT Copy, TMT Part A  
 Cut-off Sensitivity Specificity PPV NPV AUC(95% CI) p-value 
MoCA <26 88.23 67.5 12.7 99 0.829(0.748, 0.909) <0.001 
RCFT Recall <-1.10 82.4 86.1 20 98.8 0.911(0.848, 0.973) <0.001 
RCFT Copy <-0.82 70.6 78.5 15 98 0.803(0.685, 0.920) <0.001 
TMT Part A <1.03 88.2 33.9 16.47 98.79 0.568(0.437, 0.698) 0.347 
Combined Model — 94.1 89.6 32 99.64 0.939(0.870,1.000) <0.001 
   MoCA = Montreal Cognitive Assessment; RCFT = Rey Complex Figure Test; TMT = Trail      
   Making   Test; Combined model = MoCA + RCFT Copy + RCFT Recall; cut-off = the value that produced the highest Youden 
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Figure 1-2. ROC curves for the combined model (Moca + RCFT Recall + RCFT Copy) to detect 





As shown in Table 1-2 leave-one-out cross validation technique performs better from 
10-fold cross validation since the difference between observed (Delta[1]) and 
predicted value (Delta[2]) with the leave-one-out technique (dif.= 5.21x10-6) is less 
than the difference of the 10-fold cross validation (dif.= 1.5x10-4). 
(𝐸𝑟𝑟𝑜𝑟𝑖 = 𝑦𝑖 – 𝑓𝑖,  𝑖= observed value, 𝑓𝑖= predicted value) 
 
Table 1-2. Performance of 10-fold cross validation and leave one out cross validation technique 






Cross-validation technique Delta[1] Delta[2] Difference 
10-fold cross-validation 0.03057016 0.03041945 1.5x10-4 
Leave-one-out cross-validation 0.03156990 0.03156469 5.21x10-6 
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2. Confirmed MCI (n=17) vs. Possible MCI (n=91) 
Both the MoCA and RCFT Recall produced statistically significant results when 
discriminating Confirmed from Possible MCI. The optimal cut-off point, sensitivity 
and specificity, PPV and NPV for each screening instrument are listed in Table 2. The 
AUC for the RCFT Recall (AUC: 0.78, p<0.01) was higher from the AUC for the MoCA 
(AUC: 0.743, p<0.01) with a difference of 3.7% (p=0.61>0.05). Although the TMT Part 
A was not statistically significant (p>0.05), the AUC between the TMT Part A and the 
MoCA (AUC difference of 20%, p<0.01) and the RCFT Recall (AUC difference of 
23.7%, p<0.01) was significant higher, while the AUC difference between the RCFT 
Copy and the MoCA (AUC difference of 13.6%, p=0.10>0.05) and the RCFT Recall 
(AUC difference of 17.3%, p=0.11>0.05) did not reach significance. The RCFT Copy 
and the TMT Part A produced non-significant AUCs (p=0.1, p=0.54 respectively). 
The optimal combination was produced by the inclusion of MoCA, RCFT Copy and 
RCFT Recall. The combination of these tests again produced significantly higher AUC 
than the MoCA (AUC difference of 11.8%; p <0.05) and the RCFT Copy (AUC 
difference of 25.4%, p <0.001). The difference failed to reach significance when 
compared to the RCFT Recall (AUC difference of 8.1%; p =0.09>0.05). The AUCs of 
each test are illustrated in Figure 2-1 and of the combination model in Figure 2-2. 
 
 
Table 2. Diagnostic Performance of MoCA, RCFT Recall, RCFT Copy, TMT Part A  
 Cut-off Sensitivity Specificity PPV NPV AUC(95% CI) p-value 
MoCA <26 88.24 53.8 22.05 95 0.743(0.634, 0.851) <0.01 
RCFT Recall <-1.5 70.6 82.4 32.43 92.95 0.780(0.653, 0.906) <0.01 
RCFT Copy <-1.53 52.94 73.6 25.71 89.04 0.607(0.441, 0.851) 0.1 
TMT Part A <1.03 88.24 31.86 10.34 82.27 0.457(0.409, 0.676) 0.578 
Combined Model — 70.6 92.3 63.15 94.38 0.861(0.745,0.976) <0.001 
   MoCA = Montreal Cognitive Assessment; RCFT = Rey Complex Figure Test; TMT = Trail      
   Making   Test; Combined model = MoCA + RCFT Copy + RCFT Recall; cut-off = the value that produced the highest Youden 
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Figure 2-2. ROC curves for the combined model (Moca + RCFT Recall + RCFT Copy) to detect 




Once again, (Table 2-2), the Error of leave-one-out cross validation technique (dif.= 
6.01x10-5) is smaller from 10-fold cross validation (dif.= 6.53x10-4). Thus, leave-one-out 
cross validation technique evaluates better the predictive ability of the logistic 
regression. 
(𝐸𝑟𝑟𝑜𝑟𝑖 = 𝑦𝑖 – 𝑓𝑖,  𝑖= observed value, 𝑓𝑖= predicted value) 
 
Table 2-2. Performance of 10-fold cross validation and leave one out cross validation technique 







Cross-validation technique Delta[1] Delta[2] Difference 
10-fold cross-validation 0.09769609 0.09704344 6.53x10-4 
Leave-one-out cross-validation 0.09838890 0.09832875 6.01x10-5 
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3. Confirmed MCI (n=17) vs. Probable HC (n=226) 
In order to differentiate the Confirmed MCI from the Probable HC the tests that 
produced higher AUCs were the MoCA, RCFT Copy and RCFT Recall and they were 
superior to the TMT Part A (Figure 3-1). The AUC of the RCFT Recall was significantly 
higher than that shown by the MoCA (AUC difference of 10.0%, p<0.01) but it did not 
reach significance between the RCFT Copy (AUC difference of 1.8%, p=0.07). Once 
again, The TMT Part A was not statistically significant (p =0.246>0.05). 
The combination model which was consisted of the MoCA, RCFT Copy and the RCFT 
Recall, performed better than the individual screening measures (Figure 3-2). In fact, 
it produced excellent AUC, sensitivity, specificity, PPV and NPV (Table 3). The 
combined model was significantly superior to the MoCA (AUC difference of 10.8%, 
p<0.001) and the RCFT Copy (AUC difference of 9.0%, p<0.01). The combination 
model now produced an AUC difference that approached significance for the RCFT 
Recall (AUC difference of 0.74%, p =0.67(>0.05)). 
 
 
Table 3. Diagnostic Performance of MoCA, RCFT Recall, RCFT Copy, TMT Part A  
 Cut-off Sensitivity Specificity PPV NPV AUC(95% CI) p-value 
MoCA <26 88.23 73 14.42 98.56 0.864(0.788, 0.939) <0.001 
RCFT Recall <-0.8 82.35 97.34 70 98.65 0.964(0.924, 1.000) <0.001 
RCFT Copy   <-0.8 70.58 94.24 48 97.7 0.882(0.773, 0.991) <0.001 
TMT Part A <1.03 88.2 34.7 35 98.52 0.578(0.441, 0.715) 0.246 
Combined Model — 94.1 100 94.1 99.55 0.972(0.916,1.000) <0.001 
   MoCA = Montreal Cognitive Assessment; RCFT = Rey Complex Figure Test; TMT = Trail      
   Making   Test; Combined model = MoCA + RCFT Copy + RCFT Recall; cut-off = the value that produced the highest Youden 
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Figure 3-1. ROC curves for MoCA, RCFT Recall, RCFT Copy, TMT Part A model to detect 
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Figure 3-2. ROC curves the combined model (Moca + RCFT Recall + RCFT Copy) to detect 





Like the previous comparisons, 10-fold cross-validation is not the best way to 
evaluate the predictive value of the model. The difference between observed and 
predicted value (dif.= 8.72x10-5) is bigger from the difference of the leave-one-out 
cross validation technique (dif.= 3.14x10-6). Leave-one-out cross validation technique 
shows good predictive ability and is the appropriate technique to assess the accuracy 
and validity of the statistical model. 
(𝐸𝑟𝑟𝑜𝑟𝑖 = 𝑦𝑖 – 𝑓𝑖,  𝑖= observed value, 𝑓𝑖= predicted value) 
 
Table 3-2. Performance of 10-fold cross validation and leave one out cross validation technique 





Cross-validation technique Delta[1] Delta[2] Difference 
10-fold cross-validation 0.01030491 0.01021768 8.72x10-5 
Leave-one-out cross-validation 0.01003743 0.01003429 3.14x10-6 
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The current study provides evidence that the combination of the MoCA, RCFT Copy 
an RCFT Recall produces good discrimination of the patients with MCI from patients 
without MCI. In fact, the combination of these tests performed better than using 
each test individually. ROC Curve analyses for the discrimination of the Confirmed vs. 
the Possible cases showed that the combined model (MoCA, RCFT Copy an RCFT 
Recall) again exhibited better relative to each individual test, although the AUC 
difference that approached significance for the RCFT Recall suggested that an 
increased sample size might confirm the benefit of the combination model for this 
discrimination. Importantly, for the last analyses, the combination model showed 
excellent AUC, sensitivity, specificity, PPV and NPV. Consistent with the Confirmed 
MCI vs. non-MCI and the Confirmed MCI vs. the Possible MCI comparisons, the AUC 
for the Confirmed MCI vs. Probable HC produced by the combination model was 
excellent. The TMT Part A produced non-significant AUC, in all three analyses, which 
indicates that it is a poor diagnostic marker. Therefore, researchers and clinicians 
should consider adding the RCFT as an adjunct test to the more routinely used MoCA 
when screening for cognitive impairment, given that its copy and the immediate 
recall trial can be completed in less than 10 minutes. 
The primary limitation of the current study is that not everyone’s cognitive status 
was confirmed by comprehensive neuropsychological assessment. This may have 
caused some classification errors. Larger sample sizes of MCI and Possible MCI might 
have prevented the elucidation of statically significant effects, since there was a 
clear imbalance of sample size between the three cognitive classes. Thus, future 
studies should require larger sample sizes. 
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## convert xlsx file to txt file 
library(xlsx) 
file <- read.xlsx("excelfile.xlsx",sheetIndex=1) 
colnames(file) <- c("ID","MCI1HC0","Sex","Age","Educ","Moca","ReyIm","ReyCopy","TrailsA") 
write.table(file,"txtxfile.txt") 
mydata <- read.table("txtfile.txt",header=T) 
 
## view the first six rows of the data 
head(mydata) 
 
## logistic regression model for each of the tests (MoCA, RCFT Recall, RCFT Copy, TMT PartA) 
## F is a binary factor 
## xi  are continuous predictors (i=1,…,4) 
## yi is the response variable of the models 
library(MASS) 
yi <- glm(F ~xi, data = mydata, family = "binomial") 
summary(yi) 
 
##  logistic regression for the combined model (fit model) 
Test <- glm(F ~x1 + x2 + x3, data = mydata, family = "binomial") 
summary(Test) 
 










roci<- roc(F ~ prob, data = mydata) 
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## optimal cut-off point graphically for each test and the combined model 
library(Epi) 
bestpointtest<-ROC(form=F~ yi, data=mydata) 
 
## optimal cut-off point numerically for each test and the combined model 
opt <- which.max(rowSums(bestpointtest$res[, c("sens", "spec")])) 
bestpointtest$res$lr.eta[opt] 
 
## Sens, Spec, PPV, NPV for each test and the combined model 
coords(yi, bestpointtest$res$lr.eta[opt], "threshold", ret=c("sensitivity","specificity","ppv","npv")) 
 
## Tests between curves 





## 10-fold CV for the combined models 
val.10.fold<- cv.glm( data = mydata, glmfit= Test, K = 10) 
val.10.fold 
val.10.fold$delta 
## leave-one-out CV for the combined models 
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